Sun Pharmaceutical Industries Limited disclosed the outcome of its Board Meeting held on 30 October 2026. The meeting commenced at 10:45 AM (IST), was adjourned for a break, subsequently resumed, and concluded at 02:55 PM (IST).

Key Decision: Appointment of Statutory Auditors

The Board of Directors approved the appointment of new statutory auditors pursuant to mandatory auditor rotation requirements.

Current Auditor Transition

S R B C & CO LLP (SRBC), the existing Statutory Auditors, will complete its second consecutive term of five years at the conclusion of the Annual General Meeting (AGM) for the financial year 2026-27. Accordingly, SRBC will cease to hold office as Statutory Auditors upon completion of this tenure, in accordance with Section 139(2) of the Companies Act, 2013.

New Auditor Appointment

Based on the recommendation of the Audit Committee and subject to shareholder approval, the Board approved the appointment of Deloitte Haskins & Sells Chartered Accountants LLP (Firm Registration No. 117364W/W100739) as the new Statutory Auditors.

Term of Appointment

The appointment is for a term of five consecutive years, commencing from the conclusion of the AGM for the financial year 2026-27 and continuing until the conclusion of the AGM for the financial year 2031-32.

Annexure A Details

  • Name: Deloitte Haskins & Sells Chartered Accountants LLP (Firm Registration No. 117364W/W100739)
  • Reason for Change: Appointment as Statutory Auditors consequent upon completion of the second consecutive term of the existing auditors (SRBC & CO LLP) at the conclusion of the AGM for FY 2026-27
  • Effective Date: From the conclusion of the AGM for FY 2026-27, subject to shareholder approval
  • Term: Five consecutive years until conclusion of AGM for FY 2031-32
  • Brief Profile: Deloitte Haskins & Sells is a firm of Chartered Accountants registered with ICAI, part of the Deloitte network. The firm has extensive experience in audit and assurance services for large listed and multinational companies across various sectors, including pharmaceuticals, life sciences and healthcare. The firm has significant experience auditing leading pharmaceutical and healthcare companies and is supported by a multidisciplinary team of audit, tax, technology and industry specialists.
  • Disclosure of relationships between directors: Not applicable

Next Steps

The appointment is subject to approval by shareholders of the Company at the upcoming Annual General Meeting.